PDF(Pubmed)
Abstract：
Despite the existence of effective first and second line therapy options for patients with colorectal cancer, heavily treated patients have limited additional therapies. Genomic profiling is a promising tool for guiding subsequent treatment selection. Here, we describe the results of treating a colorectal cancer patient with molecularly-matched therapy based on the results of genomic profiling. The patient received a combination of afatinib and bevacizumab due to the presence of ERRFI1 variant. To our knowledge, this is the first report on the effect of EGFR inhibitors in patients with ERRFI1-altered RAS/BRAF wild-type colorectal adenocarcinoma.
摘要：
尽管结直肠癌患者存在有效的一线和二线治疗选择，大量治疗的患者有有限的额外治疗。基因组分析是指导后续治疗选择的有前途的工具。这里,我们根据基因组分析的结果描述了使用分子匹配疗法治疗结直肠癌患者的结果.由于存在ERRFI1变体，患者接受了阿法替尼和贝伐单抗的组合。据我们所知,这是首次报道EGFR抑制剂在ERRFI1改变的RAS/BRAF野生型结直肠腺癌患者中的作用.
